Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07650357 · ClinicalTrials.gov registry record · Phase 1
A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)
A Phase 1 study, sponsored by Clasp Therapeutics.
- Not yet
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
NCT07650357: Clinical Trial Phase 1 study, sponsored by Clasp Therapeutics.
NCT07650357 is a Phase 1 study that has not yet begun recruiting, run by Clasp Therapeutics. The registered enrollment target is 140 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (133% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07650357, a Phase 1 study, has not yet begun recruiting, sponsored by Clasp Therapeutics.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
Study Summary
Phase 1, open-label, multicenter study to evaluate the safety, tolerability, PK, PD, and preliminary clinical activity of CLSP 5282 when administered to HLA A\*03:01-positive adult patients with advanced solid tumors that harbor the KRas G12V mutation.
Primary Outcome
To characterize the safety and tolerability of CLSP-5282 and to determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE\[s\]).
Interventions
- DRUG CLSP-5282
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2026-07 |
| Est. Completion | 2029-07 |
| Phase | Phase 1 |
What is known before NCT07650357 opens enrollment
NCT07650357 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (133% higher).
The record links to 0 conditions, and to 1 intervention - of which CLSP-5282 is the first listed.
NCT07650357 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07650357 about?
NCT07650357 is a clinical study titled "A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)". Phase 1, open-label, multicenter study to evaluate the safety, tolerability, PK, PD, and preliminary clinical activity of CLSP 5282 when administered to HLA A\*03:01-positive adult patients with advanced solid tumors that harbor the KRas G12V mutation.
What is the current status of trial NCT07650357?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2026-07. Estimated completion is 2029-07.
What interventions are being tested in trial NCT07650357?
The interventions under investigation include: CLSP-5282 (DRUG).
Who is sponsoring clinical trial NCT07650357?
This trial is sponsored by Clasp Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07650357's enrollment target sits among peer trials
140 402nd of 2000 higher than 1,583 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia